ACT Wealth Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,830 shares of the company’s stock after selling 68 shares during the period. Johnson & Johnson accounts for approximately 0.2% of ACT Wealth Management LLC’s portfolio, making the stock its 21st biggest holding. ACT Wealth Management LLC’s holdings in Johnson & Johnson were worth $325,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.4% during the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares in the last quarter. BlackRock Inc. grew its position in Johnson & Johnson by 0.4% during the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after buying an additional 777,837 shares in the last quarter. State Street Corp grew its position in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Wellington Management Group LLP grew its position in Johnson & Johnson by 0.8% during the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after buying an additional 265,330 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Johnson & Johnson by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after buying an additional 509,818 shares in the last quarter. 68.59% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $167.60 on Monday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm has a 50 day moving average of $168.96 and a 200-day moving average of $174.29. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $440.65 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 2.99 and a beta of 0.61.
Johnson & Johnson declared that its board has authorized a stock repurchase program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.70%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.
Analyst Ratings Changes
A number of research firms recently weighed in on JNJ. Wells Fargo & Company lifted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. SVB Leerink decreased their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Citigroup decreased their price objective on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $189.78.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.